Publications by authors named "Bjorn Christian Olsen"
Background And Aims: The emergence of biologic therapy has coincided with a decline in surgery rates for Crohn's disease (CD). This study aims to describe the disease course, including intra-abdominal surgery rates, biologic therapy use, and variables associated with biologic therapy initiation in a cohort of newly diagnosed CD patients.
Methods: The Inflammatory Bowel Disease in South-Eastern Norway (IBSEN) III study is a population-based inception cohort study.
Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort.
Aliment Pharmacol Ther
August 2024
Article Synopsis
- The introduction of biologic therapies combined with a 'treat-to-target' strategy may have positively influenced the progression of ulcerative colitis (UC) in newly diagnosed patients.
- A study involving 877 adult patients with UC showed that a significant portion was in remission after one year, with low rates of disease progression and colectomy.
- The findings suggest that early treatment with biologics correlates with better outcomes, highlighting the importance of timely intervention in managing UC.
Purpose: This unselected, population-based cohort study aimed to determine the level of health-related quality of life (HRQoL) in patients with Crohn's disease (CD) and ulcerative colitis (UC) at the time of diagnosis compared with a reference population and identify the demographic factors, psychosocial measures, and disease activity markers associated with HRQoL.
Methods: Adult patients newly diagnosed with CD or UC were prospectively enrolled. HRQoL was measured using the Short Form 36 (SF-36) and Norwegian Inflammatory Bowel Disease Questionnaires.